The HDDC2 Knockout HAP1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population targeting the human HDDC2 gene in the HAP1 cell line. This loss-of-function model is generated via targeted gene disruption, yielding a heterogeneous pool of cells with ablated HDDC2 expression. The polyclonal format avoids clonal artifacts while enabling robust assessment of gene function, particularly suited for interrogating HDDC2??s uncharacterized roles in nucleotide metabolism and RNA decay.
The HAP1 host cell line is a near-haploid chronic myeloid leukemia (CML) model derived from the KBM-7 derivative, retaining the BCR-ABL1 fusion oncogene. Its haploid karyotype simplifies genotype-phenotype correlation, making it a preferred system for genetic knockout studies. The BCR-ABL1-positive background is especially relevant for leukemia biology and drug resistance research, and HAP1 cells are compatible with high-throughput screening formats.
HDDC2 encodes a predicted HD domain metal-dependent phosphohydrolase, which likely hydrolyzes nucleotide substrates and participates in nucleotide metabolism and RNA decay pathways. Representative pathway components include DCP2, a decapping enzyme, and the RNA exosome complex, suggesting a role in RNA turnover. However, upstream regulators, downstream targets, and interacting factors remain unknown. Disruption of HDDC2 may perturb nucleotide pool homeostasis or ribonucleotide recycling, but specific functions require further investigation. The mechanistic summary underscores the uncharacterized nature of HDDC2, positioning this knockout model as a discovery tool.
In the HAP1 leukemia context, HDDC2 knockout enables exploration of potential links to drug sensitivity and metabolic adaptations driven by BCR-ABL1 signaling. The near-haploid state enhances detection of subtle phenotypes, making it valuable for synthetic lethal screens and studies of nucleotide signaling in leukemogenesis. Although downstream effects are undefined, the model can reveal whether HDDC2 influences imatinib response or other kinase inhibitor efficacies.
This product supports functional genomics, nucleotide signaling research, and drug resistance screening. Validation assays include western blotting to confirm HDDC2 knockout, RT-qPCR and RNA-seq for transcriptomic profiling, and cell proliferation or drug sensitivity assays with chemotherapeutic agents. The polyclonal knockout cells provide a versatile platform for uncovering HDDC2??s biological roles and its interplay with DCP2 and the exosome. For further technical details, contact Ascent Research.
